Anzeige
Mehr »
Freitag, 19.09.2025 - Börsentäglich über 12.000 News
Die Ethereum-Vorreiter: Wie Republic Technologies die Infrastruktur der Zukunft aufbaut
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
139 Leser
Artikel bewerten:
(0)

Kelly Hyman Explains Mass Tort Litigation

UCLA and University of Florida College of Law Graduate and Attorney Kelly Hyman Offers a Professional Insight into Mass Tort Litigation.

WASHINGTON, DC / ACCESSWIRE / June 04, 2019 / A civil action involving numerous plaintiffs against one or more defendants in either state or federal court, mass tort litigation lawsuits usually arise when a defendant or defendants cause harm to multiple plaintiffs via prescribed medication, medical devices, other defective products, or from pollution and other contaminants, for example. An attorney that practices in the areas of class actions and mass tort litigation, Colorado-based attorney Kelly Hyman explains more about the process.

"Mass tort litigation allows an attorney or a group of attorney to represent several parties in otherwise individual cases," explains Hyman, an attorney in the field of mass tort litigation. "Sometimes the process may even extend to a nationwide network of lawyers across the United States, all of whom can pool resources, ideas, and information in order to ensure justice for all involved," she adds.

The four main categories of mass tort litigation, according to Kelly Hyman, cover medical device injuries, prescription drug injuries, product liability injuries, and toxic contamination. "In federal courts in the United States, mass tort lawsuits are often consolidated as multidistrict litigation," she explains.


Pharmaceutical mass torts, also known as dangerous drug mass torts, are currently the most common type of mass tort in the United States, with more than 1,000 cases filed each year across the nation, according to reports. In recent years, pharmaceutical mass torts have been brought against companies including Reglan, Risperdal, Invokana, Eliquis, and Pradaxa.

"It should be noted," Hyman explains, "that mass tort litigation routinely involves massive cost, and often relies closely on a level of efficiency and an economy of scale largely unique to the process in law."

"Requiring a huge effort from legal assistants, paralegals, and junior associates, for example, to handle and manage such a case-and the volume of paperwork which often comes with mass tort litigation-anyone looking seriously into the process would be advised to seek the advice of a specialist legal professional in the first instance," she adds, wrapping up.

A graduate of UCLA and the University of Florida College of Law, Kelly Hyman is an attorney at Denver, Colorado-based Franklin D. Azar & Associates focused on class actions and mass tort litigation. A staunch advocate for social justice and women's rights whose other interests include the law, current events, voting rights, female empowerment, and mindfulness, she is happily married to federal judge Paul G. Hyman, Jr.

Kelly Hyman - Colorado-based Top-Rated Attorney and Legal Analyst: http://kellyhymannews.com

Legal Analyst Kelly Hyman Confirmed as a Guest Speaker at Kentucky Women's Trial Attorneys Retreat: https://www.apnews.com/ACCESSWIRE/04d64b5a61f77832085d0f213c020d6d

Child Actress Kelly Hyman's Journey to Becoming a Top Class-Action Attorney and Legal Analyst: https://www.entrepreneur.com/article/332557

Contact Information:

KellyHymanNews.com
contact@kellyhymannews.com
http://kellyhymannews.com

SOURCE: Kelly Hyman



View source version on accesswire.com:
https://www.accesswire.com/547775/Kelly-Hyman-Explains-Mass-Tort-Litigation

© 2019 ACCESS Newswire
Solarbranche vor dem Mega-Comeback?
Lange galten Solaraktien als Liebling der Börse, dann kam der herbe Absturz: Zinsschock, Überkapazitäten aus China und ein Preisverfall, der selbst Marktführer wie SMA Solar, Enphase Energy oder SolarEdge massiv unter Druck setzte. Viele Anleger haben der Branche längst den Rücken gekehrt.

Doch genau das könnte jetzt die Chance sein!
Die Kombination aus KI-Explosion und Energiewende bringt die Branche zurück ins Rampenlicht:
  • Rechenzentren verschlingen Megawatt – Solarstrom bietet den günstigsten Preis je Kilowattstunde
  • Moderne Module liefern Wirkungsgrade wie Atomkraftwerke
  • hina bremst Preisdumping & pusht massiv den Ausbau
Gleichzeitig locken viele Solar-Aktien mit historischen Tiefstständen und massiven Short-Quoten, ein perfekter Nährboden für Kursrebound und Squeeze-Rally.

In unserem exklusiven Gratis-Report zeigen wir dir, welche 4 Solar-Aktien besonders vom Comeback profitieren dürften und warum jetzt der perfekte Zeitpunkt für einen Einstieg sein könnte.

Laden Sie jetzt den Spezialreport kostenlos herunter, bevor die Erholung am Markt beginnt!

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.